Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.

Ritchie MD, Haas DW, Motsinger AA, Donahue JP, Erdem H, Raffanti S, Rebeiro P, George AL, Kim RB, Haines JL, Sterling TR
Clin Infect Dis. 2006 43 (6): 779-82

PMID: 16912956 · DOI:10.1086/507101

This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenz- or nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C-->T (odds ratio, 0.254; P=.021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P<.001).

MeSH Terms (23)

Adult Anti-HIV Agents Aryl Hydrocarbon Hydroxylases Benzoxazines Case-Control Studies Chemical and Drug Induced Liver Injury Cytochrome P-450 CYP2B6 Cytochrome P-450 CYP3A Cytochrome P-450 Enzyme System Female Genes, MDR Genetic Variation Genotype HIV-1 HIV Infections Humans Liver Liver Diseases Male Nevirapine Oxazines Oxidoreductases, N-Demethylating Reverse Transcriptase Inhibitors

Connections (1)

This publication is referenced by other Labnodes entities: